Dimensional Fund Advisors LP boosted its stake in shares of Theravance Biopharma, Inc. (NASDAQ:TBPH - Free Report) by 20.8% during the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 553,713 shares of the biopharmaceutical company's stock after buying an additional 95,304 shares during the period. Dimensional Fund Advisors LP owned approximately 1.13% of Theravance Biopharma worth $5,211,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors also recently bought and sold shares of the stock. Barclays PLC grew its position in Theravance Biopharma by 14.0% in the 4th quarter. Barclays PLC now owns 74,790 shares of the biopharmaceutical company's stock valued at $704,000 after acquiring an additional 9,210 shares during the last quarter. Townsquare Capital LLC bought a new position in shares of Theravance Biopharma during the 4th quarter worth $136,000. Martingale Asset Management L P grew its position in shares of Theravance Biopharma by 7.7% during the 4th quarter. Martingale Asset Management L P now owns 58,650 shares of the biopharmaceutical company's stock worth $552,000 after buying an additional 4,200 shares in the last quarter. Invesco Ltd. grew its position in shares of Theravance Biopharma by 3.5% during the 4th quarter. Invesco Ltd. now owns 46,050 shares of the biopharmaceutical company's stock worth $433,000 after buying an additional 1,576 shares in the last quarter. Finally, Wells Fargo & Company MN grew its position in shares of Theravance Biopharma by 27.6% during the 4th quarter. Wells Fargo & Company MN now owns 21,704 shares of the biopharmaceutical company's stock worth $204,000 after buying an additional 4,695 shares in the last quarter. Hedge funds and other institutional investors own 99.10% of the company's stock.
Theravance Biopharma Stock Performance
TBPH stock traded up $0.06 during trading on Friday, reaching $9.20. 288,747 shares of the company traded hands, compared to its average volume of 273,330. Theravance Biopharma, Inc. has a 12 month low of $7.44 and a 12 month high of $10.90. The business has a 50 day simple moving average of $9.16 and a 200 day simple moving average of $9.31. The company has a market capitalization of $460.01 million, a price-to-earnings ratio of -9.11 and a beta of -0.10.
Theravance Biopharma (NASDAQ:TBPH - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The biopharmaceutical company reported ($0.27) earnings per share for the quarter, missing analysts' consensus estimates of ($0.11) by ($0.16). Theravance Biopharma had a negative net margin of 78.18% and a negative return on equity of 24.79%. The company had revenue of $15.39 million for the quarter, compared to the consensus estimate of $28.08 million. As a group, research analysts forecast that Theravance Biopharma, Inc. will post -1.09 EPS for the current year.
Insider Buying and Selling at Theravance Biopharma
In other Theravance Biopharma news, SVP Rhonda Farnum sold 4,000 shares of the stock in a transaction dated Monday, April 21st. The stock was sold at an average price of $9.00, for a total value of $36,000.00. Following the completion of the sale, the senior vice president now directly owns 370,038 shares in the company, valued at approximately $3,330,342. This trade represents a 1.07% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. 6.90% of the stock is currently owned by company insiders.
Analyst Ratings Changes
TBPH has been the topic of a number of recent research reports. HC Wainwright reissued a "buy" rating and set a $15.00 price target on shares of Theravance Biopharma in a research report on Tuesday, February 25th. StockNews.com raised Theravance Biopharma from a "hold" rating to a "buy" rating in a research report on Wednesday. Three equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat, Theravance Biopharma currently has an average rating of "Hold" and a consensus price target of $11.33.
View Our Latest Stock Report on Theravance Biopharma
About Theravance Biopharma
(
Free Report)
Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.
See Also
Before you consider Theravance Biopharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Theravance Biopharma wasn't on the list.
While Theravance Biopharma currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
